Zenas Biopharma Inc
Research Zenas Biopharma Inc (ZBIO) on Bullrun: market cap USD 2.13B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.13B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 425.15M
- Free cash flow-USD 245.48M
Valuation Snapshot
latest market cap is USD 2.13B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 10.00M | -USD 377.74M | -USD 172.35M | n/a | -8.44 | USD 110.64M | USD 78.64M | USD 242.14M |
| FY2024 | USD 5.00M | -USD 156.99M | -USD 119.81M | n/a | -11.89 | USD 319.74M | USD 1.00M | USD 312.46M |
| FY2023 | USD 50.00M | -USD 37.12M | -USD 30.55M | n/a | -24.25 | USD 56.86M | USD 21.11M | -USD 225.72M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.13B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.98B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 342.29M | n/a | n/a | n/a |
About Zenas Biopharma Inc
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zenas Biopharma Inc's market cap?
Zenas Biopharma Inc's market capitalization is USD 2.13B.
What does Zenas Biopharma Inc do?
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.